Pierre Busson

List of Publications by Year
in descending order

98 papers	5,391 citations	81900 39 h-index	88630 70 g-index
104 all docs	104 docs citations	104 times ranked	5399 citing authors

#	Article	IF	Citations
1	EBV+ tumors exploit tumor cell-intrinsic and -extrinsic mechanisms to produce regulatory T cell-recruiting chemokines CCL17 and CCL22. PLoS Pathogens, 2022, 18, e1010200.	4.7	10
2	Anti-PD-1 antibody increases NK cell cytotoxicity towards nasopharyngeal carcinoma cells in the context of chemotherapy-induced upregulation of PD-1 and PD-L1. Cancer Immunology, Immunotherapy, 2021, 70, 323-336.	4.2	25
3	Somatostatin receptor 2 expression in nasopharyngeal cancer is induced by Epstein Barr virus infection: impact on prognosis, imaging and therapy. Nature Communications, 2021, 12, 117.	12.8	34
4	Serial transplantation unmasks galectin-9 contribution to tumor immune escape in the MB49 murine model. Scientific Reports, 2021, 11, 5227.	3.3	5
5	SSTR2 in Nasopharyngeal Carcinoma: Relationship with Latent EBV Infection and Potential as a Therapeutic Target. Cancers, 2021, 13, 4944.	3.7	9
6	Radiotherapy Combined with PD-1 Inhibition Increases NK Cell Cytotoxicity towards Nasopharyngeal Carcinoma Cells. Cells, 2021, 10, 2458.	4.1	13
7	Galectin-9 promotes a suppressive microenvironment in human cancer by enhancing STING degradation. Oncogenesis, 2020, 9, 65.	4.9	52
8	Emerging therapeutic targets for nasopharyngeal carcinoma: opportunities and challenges. Expert Opinion on Therapeutic Targets, 2020, 24, 545-558.	3.4	9
9	Interferon beta increases NK cell cytotoxicity against tumor cells in patients with nasopharyngeal carcinoma via tumor necrosis factor apoptosis-inducing ligand. Cancer Immunology, Immunotherapy, 2019, 68, 1317-1329.	4.2	17
10	Interferon Î² and Anti-PD-1/PD-L1 Checkpoint Blockade Cooperate in NK Cell-Mediated Killing of Nasopharyngeal Carcinoma Cells. Translational Oncology, 2019, 12, 1237-1256.	3.7	25
11	Discrimination of the <i>V600E</i> Mutation in <i>BRAF</i> by Rolling Circle Amplification and FÃ¶rster Resonance Energy Transfer. ACS Sensors, 2019, 4, 2786-2793.	7.8	19
12	Detection of IgG directed against a recombinant form of Epstein-Barr virus BALF0/1 protein in patients with nasopharyngeal carcinoma. Protein Expression and Purification, 2019, 162, 44-50.	1.3	4
13	Structure-based design of small-molecule inhibitors of EBNA1 DNA binding blocks Epstein-Barr virus latent infection and tumor growth. Science Translational Medicine, 2019, 11, .	12.4	72
14	Radio-sensitization of head and neck cancer cells by a combination of poly(I:C) and cisplatin through downregulation of survivin and c-IAP2. Cellular Oncology (Dordrecht), 2019, 42, 29-40.	4.4	9
15	EBVâ€encoded miRNAs target ATMâ€mediated response in nasopharyngeal carcinoma. Journal of Pathology, 2018, 244, 394-407.	4.5	44
16	Establishment and characterization of new tumor xenografts and cancer cell lines from EBV-positive nasopharyngeal carcinoma. Nature Communications, 2018, 9, 4663.	12.8	106
17	Advanced microRNA-based cancer diagnostics using amplified time-gated FRET. Chemical Science, 2018, 9, 8046-8055.	7.4	32
18	Characterization of neutralizing antibodies reacting with the 213-224 amino-acid segment of human galectin-9. PLoS ONE, 2018, 13, e0202512.	2.5	12

#	Article	IF	Citations
19	Establishment of a nasopharyngeal carcinoma cell line capable of undergoing lytic Epsteinâ€“Barr virus reactivation. Laboratory Investigation, 2018, 98, 1093-1104.	3.7	45
20	EBNA1: Oncogenic Activity, Immune Evasion and Biochemical Functions Provide Targets for Novel Therapeutic Strategies against Epstein-Barr Virus- Associated Cancers. Cancers, 2018, 10, 109.	3.7	47
21	Interferon beta induces apoptosis in nasopharyngeal carcinoma cells <i>via</i> the TRAIL-signaling pathway. Oncotarget, 2018, 9, 14228-14250.	1.8	21
22	Nasopharyngeal carcinoma super-enhancerâ€“driven ETV6 correlates with prognosis. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 9683-9688.	7.1	43
23	Tollâ€like receptor 3 stimulation triggers metabolic reprogramming in pharyngeal cancer cell line through Myc, MAPK, and HIF. Molecular Carcinogenesis, 2017, 56, 1214-1226.	2.7	29
24	LMP1-mediated glycolysis induces myeloid-derived suppressor cell expansion in nasopharyngeal carcinoma. PLoS Pathogens, 2017, 13, e1006503.	4.7	103
25	Tumor exosomal microRNAs thwarting anti-tumor immune responses in nasopharyngeal carcinomas. Annals of Translational Medicine, 2017, 5, 164-164.	1.7	5
26	Review: Biological and Pharmacological Basis of Cytolytic Viral Activation in EBV-Associated Nasopharyngeal Carcinoma. , 2016, , .		2
27	Stimulation of the toll-like receptor 3 promotes metabolic reprogramming in head and neck carcinoma cells. Oncotarget, 2016, 7, 82580-82593.	1.8	24
28	Effect of Nasopharyngeal Carcinoma-Derived Exosomes on Human Regulatory T Cells. Journal of the National Cancer Institute, 2015, 107, 363.	6.3	167
29	Impact of Exogenous Galectin-9 on Human T Cells. Journal of Biological Chemistry, 2015, 290, 16797-16811.	3.4	61
30	Plasma miR-200b in ovarian carcinoma patients: distinct pattern of pre/post-treatment variation compared to CA-125 and potential for prediction of progression-free survival. Oncotarget, 2015, 6, 36815-36824.	1.8	29
31	Expression of two parental imprinted miRNAs improves the risk stratification of neuroblastoma patients. Cancer Medicine, 2014, 3, 998-1009.	2.8	11
32	miR-31 is consistently inactivated in EBV-associated nasopharyngeal carcinoma and contributes to its tumorigenesis. Molecular Cancer, 2014, 13, 184.	19.2	39
33	Treatment of Nasopharyngeal Carcinoma Cells with the Histone-Deacetylase Inhibitor Abexinostat: Cooperative Effects with Cis-platin and Radiotherapy on Patient-Derived Xenografts. PLoS ONE, 2014, 9, e91325.	2.5	34
34	Consistent high concentration of the viral microRNA BART17 in plasma samples from nasopharyngeal carcinoma patients - evidence of non-exosomal transport. Virology Journal, 2013, 10, 119.	3.4	47
35	Epstein-Barr Virus and the Pathogenesis of Nasopharyngeal Carcinomas. Advances in Experimental Medicine and Biology, 2013, , 42-60.	1.6	9
36	Identification of a recurrent transforming UBR5â€“ZNF423 fusion gene in EBV â€associated nasopharyngeal carcinoma. Journal of Pathology, 2013, 231, 158-167.	4.5	43

#	Article	IF	Citations
37	Constitutive activation of distinct NF-Î°B signals in EBV-associated nasopharyngeal carcinoma. Journal of Pathology, 2013, 231, 311-322.	4.5	119
38	Cellular Interactions in Nasopharyngeal Carcinomas. Advances in Experimental Medicine and Biology, 2013, , 82-100.	1.6	3
39	Biological Tools for NPC Population Screening and Disease Monitoring. Advances in Experimental Medicine and Biology, 2013, , 101-117.	1.6	1
40	A novel monoclonal antibody for detection of galectin-9 in tissue sections: application to human tissues infected by oncogenic viruses. Infectious Agents and Cancer, 2012, 7, 16.	2.6	13
41	Toll-like receptor 3 in Epstein-Barr virus-associated nasopharyngeal carcinomas: consistent expression and cytotoxic effects of its synthetic ligand poly(A:U) combined to a Smac-mimetic. Infectious Agents and Cancer, 2012, 7, 36.	2.6	18
42	CD44+ Cancer Stem-Like Cells in EBV-Associated Nasopharyngeal Carcinoma. PLoS ONE, 2012, 7, e52426.	2.5	69
43	Inhibition of NOTCH3 signalling significantly enhances sensitivity to cisplatin in EBVâ€associated nasopharyngeal carcinoma. Journal of Pathology, 2012, 226, 471-481.	4.5	62
44	Profiling of Epstein-Barr virus-encoded microRNAs in nasopharyngeal carcinoma reveals potential biomarkers and oncomirs. Cancer, 2012, 118, 4634-4634.	4.1	16
45	Hostâ€"tumor interactions in nasopharyngeal carcinomas. Seminars in Cancer Biology, 2012, 22, 127-136.	9.6	81
46	Profiling of Epsteinâ€Barr virusâ€encoded microRNAs in nasopharyngeal carcinoma reveals potential biomarkers and oncomirs. Cancer, 2012, 118, 698-710.	4.1	135
47	Expression of miR-487b and miR-410 encoded by 14q32.31 locus is a prognostic marker in neuroblastoma. British Journal of Cancer, 2011, 105, 1352-1361.	6.4	91
48	Rapid obtention of stable, bioluminescent tumor cell lines using a tCD2-luciferase chimeric construct. BMC Biotechnology, 2011, 11, 26.	3.3	1
49	Significance of Plk1 regulation by miRâ€100 in human nasopharyngeal cancer. International Journal of Cancer, 2010, 126, 2036-2048.	5.1	126
50	Poly(I:C) induces intense expression of c-IAP2 and cooperates with an IAP inhibitor in induction of apoptosis in cancer cells. BMC Cancer, 2010, 10, 327.	2.6	22
51	Identification of a novel 12p13.3 amplicon in nasopharyngeal carcinoma. Journal of Pathology, 2010, 220, 97-107.	4.5	44
52	A Crucial Role for Kupffer Cell-Derived Galectin-9 in Regulation of T Cell Immunity in Hepatitis C Infection. PLoS ONE, 2010, 5, e9504.	2.5	161
53	Extra-cellular release and blood diffusion of BART viral micro-RNAs produced by EBV-infected nasopharyngeal carcinoma cells. Virology Journal, 2010, 7, 271.	3.4	113
54	Blood diffusion and Th1-suppressive effects of galectin-9â€"containing exosomes released by Epstein-Barr virusâ€"infected nasopharyngeal carcinoma cells. Blood, 2009, 113, 1957-1966.	1.4	350

#	Article	IF	Citations
55	Le point de vue du biologiste: peut-on dÃ©finir les bases biologiques du Â« phÃ©notype CAPI Â» ?. Oncologie, 2008, 10, 722-727.	0.7	0
56	Recurrent Overexpression of c-IAP2 in EBV-Associated Nasopharyngeal Carcinomas: Critical Role in Resistance to Toll-like Receptor 3-Mediated Apoptosis. Neoplasia, 2008, 10, 1183-IN7.	5.3	45
57	Efficacy of Systemically Administered Mutant Vesicular Stomatitis Virus (VSVÎ”51) Combined with Radiation for Nasopharyngeal Carcinoma. Clinical Cancer Research, 2008, 14, 4891-4897.	7.0	16
58	Nuclear Factor-Y and Epstein Barr Virus in Nasopharyngeal Cancer. Clinical Cancer Research, 2008, 14, 984-994.	7.0	10
59	Aberrant methylation of p16, DLEC1, BLU and E-cadherin gene promoters in nasopharyngeal carcinoma biopsies from Tunisian patients. Anticancer Research, 2008, 28, 2161-7.	1.1	33
60	Imaging and Modulating Antisense Microdistribution in Solid Human Xenograft Tumor Models. Clinical Cancer Research, 2007, 13, 5935-5941.	7.0	5
61	Imaging the Modulation of Adenoviral Kinetics and Biodistribution for Cancer Gene Therapy. Molecular Therapy, 2007, 15, 921-929.	8.2	19
62	Biological characterization of two xenografts derived from human CUPs (carcinomas of unknown) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	2.6	4
63	Exosomes released by EBV-infected nasopharyngeal carcinoma cells convey the viral Latent Membrane Protein 1 and the immunomodulatory protein galectin 9. BMC Cancer, 2006, 6, 283.	2.6	218
64	Absence of caspase 3 activation in neoplastic cells of nasopharyngeal carcinoma biopsies predicts rapid fatal outcome. Modern Pathology, 2005, 18, 877-885.	5.5	24
65	Conventional and array-based comparative genomic hybridization analysis of nasopharyngeal carcinomas from the Mediterranean area. Cancer Genetics and Cytogenetics, 2005, 157, 140-147.	1.0	27
66	TRAF interactions with raft-like buoyant complexes, better than TRAF rates of degradation, differentiate signaling by CD40 and EBV latent membrane protein 1. International Journal of Cancer, 2005, 113, 267-275.	5.1	28
67	In Nasopharyngeal Carcinoma Cells, Epstein-Barr Virus LMP1 Interacts with Galectin 9 in Membrane Raft Elements Resistant to Simvastatin. Journal of Virology, 2005, 79, 13326-13337.	3.4	62
68	Combination Bcl-2 Antisense and Radiation Therapy for Nasopharyngeal Cancer. Clinical Cancer Research, 2005, 11, 8131-8144.	7.0	59
69	EBV latent membrane protein 1 abundance correlates with patient age but not with metastatic behavior in north African nasopharyngeal carcinomas. Virology Journal, 2005, 2, 39.	3.4	62
70	Potential Utility of BimS as a Novel Apoptotic Therapeutic Molecule. Molecular Therapy, 2004, 10, 533-544.	8.2	29
71	A Conditionally Replicating Adenovirus for Nasopharyngeal Carcinoma Gene Therapy. Molecular Therapy, 2004, 9, 804-817.	8.2	27
72	EBV-associated nasopharyngeal carcinomas: from epidemiology to virus-targeting strategies. Trends in Microbiology, 2004, 12, 356-360.	7.7	119

#	Article	IF	Citations
73	Similar BCL-X but different BCL-2 levels in the two age groups of north African nasopharyngeal carcinomas. Cancer Detection and Prevention, 2003, 27, 250-255.	2.1	43
74	Apoptosis and TRAF-1 cleavage in Epstein-Barr virus-positive nasopharyngeal carcinoma cells treated with doxorubicin combined with a farnesyl-transferase inhibitor. Biochemical Pharmacology, 2003, 65, 423-433.	4.4	16
75	Two Distinct Gb3/CD77 Signaling Pathways Leading to Apoptosis Are Triggered by Anti-Gb3/CD77 mAb and Verotoxin-1. Journal of Biological Chemistry, 2003, 278, 45200-45208.	3.4	71
76	Efficacy of targeted FasL in nasopharyngeal carcinoma. Molecular Therapy, 2003, 8, 964-973.	8.2	29
77	Use of Adenovirus Vectors Expressing Epstein-Barr Virus (EBV) Immediate-Early Protein BZLF1 or BRLF1 To Treat EBV-Positive Tumors. Journal of Virology, 2002, 76, 10951-10959.	3.4	53
78	Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors. Cancer Research, 2002, 62, 1920-6.	0.9	133
79	Adenovirus-p53 gene therapy in human nasopharyngeal carcinoma xenografts. Radiotherapy and Oncology, 2001, 61, 309-312.	0.6	13
80	Growth Transformation of Primary Epithelial Cells with a NPC-Derived Epsteinâ€“Barr Virus Strain. Virology, 2001, 288, 223-235.	2.4	27
81	Radiation-induced expression of functional Fas ligand in EBV-positive human nasopharyngeal carcinoma cells. , 2000, 86, 229-237.		31
82	Evidence of LMP1-TRAF3 interactions in glycosphingolipid-rich complexes of lymphoblastoid and nasopharyngeal carcinoma cells. , 1999, 81, 645-649.		43
83	High Concentration of the EBV Latent Membrane Protein 1 in Glycosphingolipid-Rich Complexes from both Epithelial and Lymphoid Cells. Virology, 1997, 228, 285-293.	2.4	49
84	Expression of the DNase Encoded by the BGLF5 Gene of Epsteinâ€“Barr Virus in Nasopharyngeal Carcinoma Epithelial Cells. Virology, 1996, 222, 64-74.	2.4	31
85	Epstein-Barr virus (EBV) latent membrane protein 1 increases HLA class II expression in an EBV-negative B cell line. European Journal of Immunology, 1994, 24, 1467-1470.	2.9	37
86	Phase II trial of recombinant interferon gamma in refractory undifferentiated carcinoma of the nasopharynx. Head and Neck, 1993, 15, 115-118.	2.0	13
87	Cytogenetic studies in three xenografted nasopharyngeal carcinomas. Cancer Genetics and Cytogenetics, 1993, 66, 11-15.	1.0	25
88	Elevated expression of ICAM1 (CD54) and minimal expression of LFA3 (CD58) in epstein-barr-virus-positive nasopharyngeal carcinoma cells. International Journal of Cancer, 1992, 50, 863-867.	5.1	39
89	Consistent transcription of the Epstein-Barr virus LMP2 gene in nasopharyngeal carcinoma. Journal of Virology, 1992, 66, 3257-3262.	3.4	184
90	Alterations of the p53 gene in nasopharyngeal carcinoma. Journal of Virology, 1992, 66, 3768-3775.	3.4	127

#	Article	IF	Citations
91	Cytotoxic potential despite impaired activation pathways in T lymphocytes infiltrating nasopharyngeal carcinoma. International Journal of Cancer, 1991, 47, 362-370.	5.1	55
92	Expression of the Epstein-Barr virus BamHI A fragment in nasopharyngeal carcinoma: evidence for a viral protein expressed in vivo. Journal of Virology, 1991, 65, 6252-6259.	3.4	120
93	Structure and regulation of the Blast-2/CD23 antigen in epithelial cells from nasopharyngeal carcinoma. International Immunology, 1990, 2, 1159-1166.	4.0	10
94	Novel transcription from the Epstein-Barr virus terminal EcoRI fragment, DIJhet, in a nasopharyngeal carcinoma. Journal of Virology, 1990, 64, 4948-4956.	3.4	146
95	Expression of thec-fgr related transcripts in epstein-barr virus-associated malignancies. International Journal of Cancer, 1988, 42, 29-35.	5.1	11
96	Expression of Epsteinâ€Barr virusâ€encoded proteins in nasopharyngeal carcinoma. International Journal of Cancer, 1988, 42, 329-338.	5.1	483
97	Epstein-Barr virus-containing epithelial cells from nasopharyngeal carcinoma produce interleukin 1 alpha.. Proceedings of the National Academy of Sciences of the United States of America, 1987, 84, 6262-6266.	7.1	68
98	B-cell-derived interleukin-1. Annales De L'Institut Pasteur Immunologie, 1987, 138, 599-603.	0.8	1